Intestinal Disease
42
4
6
20
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 42 trials
100.0%
+13.4% vs benchmark
17%
7 trials in Phase 3/4
25%
5 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 20 completed trials
Clinical Trials (42)
Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
Immune Responses to Gluten
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
Gut Leakage' in Dengue
Outcomes of Outpatients in an Gut Microbiota Clinic
Study of Normal Intestinal Development and Disease in Premature and Term Neonates
Gluten-free Diet in PSC and IBD
A Study to Evaluate Safety and Efficacy of PBK_M2502
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
CRC Detection Reliable Assessment With Blood
DEscripitive Patient Analysis to Enable Risk-based Quality Improvement Measures in a lArge iNternal mediCIne grouP Practice
SGM-101 in Colorectal Brain Metastases.
Effect of Probiotics on Patients With Congenital Heart Disease Following Cardiopulmonary Bypass
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
Mental Stress and Bowel Preparation Quality
A Study to Evaluate Safety and Efficacy of PBK_M2101
Gut Microbial Changes After Periodontal Treatment
Bacteriology of sUrGical Site INfection Following Surgery for Intestinal Failure
Endoscopist and Endoscope Motions During Colonoscopy